ArticleCell biochemistry and biophysics2025
Identification Cuproptosis-related Genes Signature to Predict the Prognosis of Lung Cancer.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cuproptosis, a recently characterized form of regulated cell death driven by copper ions, has been implicated in cancer progression, yet its prognostic significance in lung adenocarcinoma (LUAD) remains unclear. In this study, we explored the expression patterns and prognostic relevance of 19 cuproptosis-related genes (CuRGs) using multiple public datasets. Consensus clustering analysis stratified LUAD patients into two distinct molecular subtypes with significant differences in clinical outcomes and immune characteristics. Differentially expressed genes (DEGs) between the two subtypes were identified, and functional enrichment analysis revealed significant associations with immune pathways. A prognostic risk signature (CuRG_score) comprising five genes was constructed using LASSO-Cox regression and validated across three independent GEO datasets. The CuRG_score effectively stratified patients into high- and low-risk groups with significant differences in overall survival. The AUC values were 0.761, 0.618, and 0.642 across the datasets, respectively, demonstrating strong predictive power. Further analysis revealed that high-risk patients exhibited immunosuppressive features, including lower infiltration of CD8+T cells and NK cells. Moreover, immune checkpoint expression and immunophenoscore (IPS) analysis suggested that low-risk patients may benefit more from immunotherapy. In conclusion, our study identifies a novel CuRG-based molecular signature that serves as a robust predictor of LUAD prognosis and offers potential guidance for personalized immunotherapy strategies.
Indexed as
Identifiers
40658149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.